>98%
Purity HPLC
COA
Every batch
EU
Fulfilment
Discreet
Shipping
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a stabilised analogue of the ACTH 4-10 fragment, engineered to resist enzymatic degradation while retaining and amplifying the neurological activity of its parent sequence. Unlike ACTH itself, Semax carries no hormonal activity — its effects are confined to the central nervous system.
Research has focused primarily on its ability to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), two key proteins responsible for neuronal survival, synaptic plasticity, and cognitive performance. Studies have also documented significant effects on dopaminergic and serotonergic transmission.
Semax has been approved as a pharmaceutical drug in Russia and Ukraine for the treatment of stroke, transient ischaemic attacks, and cognitive impairment, making it one of the few peptides in this category with an established clinical history.
Key research areas include:
– BDNF and NGF upregulation
– Cognitive enhancement and memory consolidation
– Neuroprotection following ischaemic injury
– Dopaminergic and serotonergic modulation
– Anxiety and stress response regulation
– Attention and focus enhancement
- BDNF & NGF Upregulation
Semax has been shown to significantly increase expression of BDNF and NGF in the hippocampus and cortex. These neurotrophins play a critical role in synaptic plasticity, long-term potentiation, and neuronal survival, providing a mechanistic basis for the cognitive effects observed in research models. - Neuroprotection
Multiple studies have demonstrated Semax’s ability to reduce neuronal death following ischaemic injury. It suppresses the expression of pro-inflammatory cytokines and oxidative stress markers in brain tissue, while simultaneously upregulating protective gene expression pathways. - Dopaminergic & Serotonergic Modulation
Research has documented Semax’s ability to modulate dopamine and serotonin transmission in the prefrontal cortex and limbic system, with implications for mood regulation, motivation, and stress resilience. - Cognitive Performance
Animal studies have consistently demonstrated improvements in learning speed, memory consolidation, and attention under Semax administration. Effects appear to be mediated primarily through BDNF-dependent pathways in the hippocampus. - Stroke & Ischaemia
Clinical research conducted in Russia demonstrated significant reduction in neurological deficit scores and accelerated functional recovery in stroke patients treated with Semax, supporting its pharmaceutical approval in that country.
Key References:
– Dolotov OV et al. Semax, an analogue of ACTH 4-10, regulates BDNF and NGF expression. J Neurochem. 2006.
– Gusev EI et al. Neuroprotective effects of Semax in stroke patients. Cerebrovasc Dis. 1997.
– Inozemtseva LS et al. Semax affects dopaminergic system activity. Bull Exp Biol Med. 2008.- BDNF & NGF Upregulation
| Parameter | Detail |
| Peptide | Semax (ACTH 4-10 Analogue) |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular Weight | 809.91 g/mol |
| CAS Number | 80714-61-0 |
| Appearance | White lyophilised powder |
| Purity | >99% (HPLC) |
| Vial Size | 10mg |
| Storage | -20°C, protect from light and moisture |
| Reconstitution | Bacteriostatic water or sterile saline |
| Shelf Life | 24 months (lyophilised) / 30 days (reconstituted, refrigerated) |
| Format | Lyophilised powder, single-use research vial |
Reviews
There are no reviews yet.